News: Deals: Reports

Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Resource Guide Small Business Makeovers Questions & Answers Small Business Video 100 Best Places to Launch FSB 100 Fortune Small Business Fortune 500 Brainstorm Tech Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts

CV Therapeutics Inc & Astellas Pharma Inc	Update Date: 02/20/09
Date Announced: 01/27/09
Value (million $USD): 981.2 million U.S. Dollar

Status: Pending

TRANSACTION DETAILS
Date Announced	01/27/09
Date Originally Announced	01/27/09
Format	Merger	Acquisition techniques	Unsolicited Deal
Attitude	Unsolic.	Agency	n/a
Value	981.2 million U.S. Dollar	Advisor Fees	n/a

SYNOPSIS
US - Astellas Pharma Inc planned to launch an unsolicited offer to acquire all the outstanding common stock of CV Therapeutics Inc, a biopharmaceutical company, for $16 in cash per share, or a total value of $981.226 mil.

TARGET
Name	CV Therapeutics Inc (CVTX)
Industries	Medicinal chemicals and botanical products; Biological products, except diagnostic substances
City	Palo Alto
State	CA
Nation	United States
Incorporated in	DE
Public Status	Public
Business Description	CV Therapeutics Inc, located in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the development, discovery and commercialization of drugs for the treatment of cardiovascular diseases. Its approved product, Ranexa (ranolazine extended-release tablets) is indicated for the treatment of chronic angina. The company also develops Ranexa, which is in Phase III clinical development stage for the treatment of acute coronary syndrome. It was founded in 1990.
Advisors	Barclays Capital
Target Sales	135.0 million U.S. Dollar

ACQUIROR
Name	Astellas Pharma Inc (Tokyo 1 : 4503)
Industries	Medicinal chemicals and botanical products; Biological products, except diagnostic substances; Drugs, drug proprietaries, and druggists' sundries
City	Tokyo
State	n/a
Nation	Japan
Incorporated in	n/a
Public Status	Public
Business Description	Astellas Pharma Inc, located in Tokyo, Japan, manufactures and wholesales prescription pharmaceuticals intended for final consumption, including biotech products and antibiotics. Its products include Harnal, Lipitor, Prograf, various antibiotics, metabolic drugs, and painkillers. The company was founded in 1923.
Advisors	Lazard
Acquiror Sales	10.66 billion U.S. Dollar 966.33 billion Japanese Yen

Home Portfolio Calculators Contact Us Newsletters Podcasts RSS Mobile Widgets Site Map User Preferences Advertise with Us
Magazine Customer Service Download Fortune Lists Reprints Career Opportunities Special Sections Conferences Business Leader Council

Live Quotes automatically refresh, but individual equities are delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer

Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.